Men's Health News

RSS

Study: Men who do moderate-to-heavy intensity exercise are less likely to have stroke

Men who regularly take part in moderate-to-heavy intensity exercise such as jogging, tennis or swimming may be less likely to have a stroke than people who get no exercise or only light exercise, such as walking, golfing, or bowling, according to a study published in the November 24, 2009, print issue of Neurology ®, the medical journal of the American Academy of Neurology.

24 Nov 2009

"Hotline" report on finasteride for prevention of prostate cancer

In response to a recent New York Times article that questions why currently available medications designed to treat and prevent some cancers are being ignored, ECRI Institute, an independent nonprofit organization, is offering a roadmap to the evidence on Finasteride for Prevention of Prostate Cancer for free download.

20 Nov 2009

FDA acknowledges Dendreon's amended BLA for PROVENGE as a complete response

Dendreon Corporation today announced that the U.S. Food and Drug Administration (FDA) provided written acknowledgement that the Company's amended Biologics License Application (BLA) for PROVENGE® (sipuleucel-T) is a complete response. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of May 1, 2010, by which time it will respond to Dendreon's amended BLA. Dendreon is seeking licensure for PROVENGE for men with metastatic castrate-resistant prostate cancer (CRPC).

20 Nov 2009

HHS Secretary commended for her statement on government medical panel

U.S. Health and Human Services Secretary Kathleen Sebelius is to be commended for publicly stating the government panel opposing mammograms is "an outside independent panel of doctors and scientists who ... do not set federal policy and ... don't determine what services are covered by the federal government."

20 Nov 2009

Data from second positive pivotal study of PSD502 for treatment of PE presented

At the annual meeting of the Sexual Medicine Society of North America (SMSNA), Inc. in San Diego, Sciele Pharma, Inc., a Shionogi Company and Plethora Solutions Limited, a wholly owned subsidiary of Plethora Solutions Holdings PLC ("Plethora")., today presented data from its second positive pivotal study of PSD502 for the treatment of premature ejaculation (PE).

20 Nov 2009

Positive results from Sciele Pharma's second pivotal study of PSD502 for the treatment of PE

At the annual meeting of the Sexual Medicine Society of North America, Inc. in San Diego, Sciele Pharma, Inc., a Shionogi Company, and Plethora Solutions Limited, a wholly owned subsidiary of Plethora Solutions Holdings PLC, today presented data from its second positive pivotal study of PSD502 for the treatment of premature ejaculation (PE).

19 Nov 2009

Annual conference to discuss male infertility and tackling falling birth rates across Europe

Male infertility and tackling falling birth rates across Europe will be among the topics addressed at this year's British Andrology Society's annual conference at Queen's University in Belfast.

19 Nov 2009

Gene therapy may hold promise for cryptorchid individuals risking infertility

EGR4 is a master gene responsible for fertility in cryptorchidism. Is gene therapy going to replace surgery?

18 Nov 2009

Phase III randomized clinical trial for Alpharadin to be commenced

International prostate cancer expert Dr. Oliver Sartor of Tulane Cancer Center is the first oncologist in the United States to offer patients an experimental new treatment for late-stage prostate cancer through a multi-center clinical trial that is currently recruiting patients at 100 sites across 20 countries worldwide.

18 Nov 2009

Interim data from Hollis-Eden Pharmaceuticals' Apoptone Phase I/II clinical trial presented

Hollis-Eden Pharmaceuticals, Inc., today reported preliminary results of its ongoing Phase I/II clinical trial with Apoptone® (HE3235) for hormone-resistant prostate cancer (also called castrate-resistant prostate cancer or CRPC). Presented at the Molecular Targets and Cancer Therapeutics Conference, which is co-sponsored by the AACR, NCI and EORTC, the poster is titled: "Results of preclinical and clinical Phase I/II open-label dose-ranging trial with HE3235, a synthetic adrenal hormone, in Castrate Resistant Prostate Cancer (CRPC)."

16 Nov 2009

LA BioMed to participate in a national study of the effectiveness of testosterone

Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed) announced today that it will participate in a large national study of the effectiveness of testosterone as a treatment for anemia, cardiovascular disease, decreased vitality, impaired memory and sexual function, loss of muscle mass and other health conditions that affect older men.

13 Nov 2009

Cancer screening methods are not perfect: Experts

In a recent New York Times article, the American Cancer Society (ACS) ignited a major controversy over the benefits of cancer screening, specifically with regards to their breast and prostate cancer guidelines. In the article, Dr. Otis Brawley, chief medical officer of the ACS, responded to a study in the current issue of the Journal of the American Medical Association.

11 Nov 2009

Prostate size growth not necessarily a predictor of development of cancer

New Mayo Clinic research studied the association between prostate-specific antigen (PSA) levels and prostate size and found that routine annual evaluation of prostate growth is not necessarily a predictor for the development of prostate cancer. However the study suggests that if a man's PSA level is rising quickly, a prostate biopsy is reasonable to determine if he has prostate cancer.

11 Nov 2009

First human study to measure effects of BPA on male reproductive system

High levels of workplace exposure to Bisphenol-A may increase the risk of reduced sexual function in men, according to a Kaiser Permanente study appearing in the journal Human Reproduction, published by Oxford Journals.

11 Nov 2009

Prostatitis is a psychoneuromuscular condition: Study

In the November 2009 issue of the Journal of Urology, Stanford Medical School researcher Dr. Rodney Anderson and researchers at the National Center for Pelvic Pain Research, in a new study, demonstrated a high correlation between the location of painful trigger points inside the pelvic floor muscles of men with chronic prostatitis and the location in the body where they routinely complain of pain.

10 Nov 2009

Study reveals that male factor infertility is associated with a number of medical comorbidities

The December issue of European Urology, the official journal of the European Association of Urology, features an article entitled 'Are Infertile Men Less Healthy than Fertile Men? Results of a Prospective Case-Control Survey' by Dr. Andrea Salonia et al. The conclusion is that male factor infertility is associated with a number of medical comorbidities, as objectively scored with the hospital-based Charlson Comorbidity Index.

10 Nov 2009

Chicago Prostate Cancer Center offers free prostate cancer guide

Prostate cancer is the second most common cancer in American men. One in six men will be diagnosed during his lifetime, according to the American Cancer Society.

9 Nov 2009

Elevated PSA levels in men are not necessarily a predictor of the need for a prostate biopsy: Study

Researchers at Wake Forest University School of Medicine and the University of Wisconsin-Madison have discovered that some elevated prostate-specific antigen (PSA) levels in men may be caused by a hormone normally occurring in the body, and are not necessarily a predictor of the need for a prostate biopsy.

7 Nov 2009

Men's Wellness Center launched at AHF Blair Underwood Healthcare Center’

On Thursday, November 5th, AIDS Healthcare Foundation (AHF), the largest global AIDS organization, which provides medical care and/or services to more than 120,000 individuals in 22 countries worldwide, opened a Men's Wellness Center at the new ‘AHF Blair Underwood Healthcare Center’ located in Washington D.C.

7 Nov 2009

Changes in PSA over time aid prostate cancer detection

The November issue of European Urology, the official journal of the European Association of Urology, features an article focussing on prostate specific antigen (PSA) velocity and early cancer detection. It has been suggested that changes in PSA over time aid prostate cancer detection.

6 Nov 2009